|
|
Blood, 1 January 2004, Vol. 103, No. 1, pp. 301-308.
Prepublished online as a Blood First Edition Paper on September 22, 2003; DOI 10.1182/blood-2003-06-2066.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells
Ya-Wei Qiang,
Lei Yao,
Giovanna Tosato, and
Stuart Rudikoff
From the Laboratory of Cellular and Molecular Biology and Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Multiple myeloma (MM) is an incurable form of cancer characterized by accumulation of malignant plasma cells in the bone marrow. During the course of this disease, tumor cells cross endothelial barriers and home to the bone marrow. In latter stages, myeloma cells extravasate through blood vessels and may seed a variety of organs. Insulin-like growth factor I (IGF-I) is one of several growth factors shown to promote the growth of MM cells. In the current study, we have assessed the ability of IGF-I to serve additionally as a chemotactic factor affecting the mobility and invasive properties of these cells. Results indicate that IGF-I promotes transmigration through vascular endothelial cells and bone marrow stromal cell lines. Analysis of endogenous signaling pathways revealed that protein kinase D/protein kinase Cµ (PKD/PKCµ) and RhoA were both activated in a phosphatidylinositol 3-kinase (PI-3K)–dependent manner. Inhibition of PI-3K, PKCs, or Rho-associated kinase by pharmacologic inhibitors abrogated migration, whereas mitogen-activated protein kinase (MAPK), Akt, and p70S6 kinase inhibitors had no effect. These results suggest that IGF-I promotes myeloma cell migration by activation of PI-3K/PKCµ and PI-3K/RhoA pathways independent of Akt. The identification of IGF-I as both a proliferative and migratory factor provides a rational basis for the development of targeted therapeutic strategies directed at IGF-I in the treatment of MM.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Czondor, K. Ellwanger, Y. F. Fuchs, S. Lutz, M. Gulyas, I. M. Mansuy, A. Hausser, K. Pfizenmaier, and K. Schlett
Protein Kinase D Controls the Integrity of Golgi Apparatus and the Maintenance of Dendritic Arborization in Hippocampal Neurons
Mol. Biol. Cell,
April 1, 2009;
20(7):
2108 - 2120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-E. Choi, S.-s. Lee, D. A. Sunde, I. Huizar, K. L. Haugk, V. J. Thannickal, R. Vittal, S. R. Plymate, and L. M. Schnapp
Insulin-like Growth Factor-I Receptor Blockade Improves Outcome in Mouse Model of Lung Injury
Am. J. Respir. Crit. Care Med.,
February 1, 2009;
179(3):
212 - 219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Birmann, R. M. Tamimi, E. Giovannucci, B. Rosner, D. J. Hunter, P. Kraft, C. Mitsiades, K. C. Anderson, and G. A. Colditz
Insulin-like Growth Factor-1- and Interleukin-6-related Gene Variation and Risk of Multiple Myeloma
Cancer Epidemiol. Biomarkers Prev.,
January 1, 2009;
18(1):
282 - 288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kakinuma, B. C. Roy, Y. Zhu, Y. Wang, and R. Kiyama
Kank regulates RhoA-dependent formation of actin stress fibers and cell migration via 14-3-3 in PI3K-Akt signaling
J. Cell Biol.,
October 14, 2008;
181(3):
537 - 549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Qiang, J. D. Shaughnessy Jr, and S. Yaccoby
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
Blood,
July 15, 2008;
112(2):
374 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kim, H.-R. Jang, J.-H. Kim, S.-M. Noh, K.-S. Song, J.-S. Cho, H.-Y. Jeong, J. C. Norman, P. T. Caswell, G. H. Kang, et al.
Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion
Carcinogenesis,
March 1, 2008;
29(3):
629 - 637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kobune, H. Chiba, J. Kato, K. Kato, K. Nakamura, Y. Kawano, K. Takada, R. Takimoto, T. Takayama, H. Hamada, et al.
Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism
Mol. Cancer Ther.,
June 1, 2007;
6(6):
1774 - 1784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. van Golen, T. S. Schwab, B. Kim, M. E. Soules, S. Su Oh, K. Fung, K. L. van Golen, and E. L. Feldman
Insulin-Like Growth Factor-I Receptor Expression Regulates Neuroblastoma Metastasis to Bone.
Cancer Res.,
July 1, 2006;
66(13):
6570 - 6578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Girnita, C. All-Ericsson, M. A. Economou, K. Astrom, M. Axelson, S. Seregard, O. Larsson, and L. Girnita
The Insulin-Like Growth Factor-I Receptor Inhibitor Picropodophyllin Causes Tumor Regression and Attenuates Mechanisms Involved in Invasion of Uveal Melanoma Cells
Clin. Cancer Res.,
February 15, 2006;
12(4):
1383 - 1391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Menu, H. Jernberg-Wiklund, T. Stromberg, H. De Raeve, L. Girnita, O. Larsson, M. Axelson, K. Asosingh, K. Nilsson, B. Van Camp, et al.
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
Blood,
January 15, 2006;
107(2):
655 - 660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Stromberg, S. Ekman, L. Girnita, L. Y. Dimberg, O. Larsson, M. Axelson, J. Lennartsson, U. Hellman, K. Carlson, A. Osterborg, et al.
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells
Blood,
January 15, 2006;
107(2):
669 - 678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Celil and P. G. Campbell
BMP-2 and Insulin-like Growth Factor-I Mediate Osterix (Osx) Expression in Human Mesenchymal Stem Cells via the MAPK and Protein Kinase D Signaling Pathways
J. Biol. Chem.,
September 9, 2005;
280(36):
31353 - 31359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Qiang, K. Walsh, L. Yao, N. Kedei, P. M. Blumberg, J. S. Rubin, J. Shaughnessy Jr, and S. Rudikoff
Wnts induce migration and invasion of myeloma plasma cells
Blood,
September 1, 2005;
106(5):
1786 - 1793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Carvajal-Vergara, S. Tabera, J. C. Montero, A. Esparis-Ogando, R. Lopez-Perez, G. Mateo, N. Gutierrez, M. Parmo-Cabanas, J. Teixido, J. F. San Miguel, et al.
Multifunctional role of Erk5 in multiple myeloma
Blood,
June 1, 2005;
105(11):
4492 - 4499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Rozengurt, O. Rey, and R. T. Waldron
Protein Kinase D Signaling
J. Biol. Chem.,
April 8, 2005;
280(14):
13205 - 13208.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ghias, C. Ma, V. Gandhi, L. C. Platanias, N. L. Krett, and S. T. Rosen
8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: Role in induction of apoptosis in multiple myeloma
Mol. Cancer Ther.,
April 1, 2005;
4(4):
569 - 577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Raje, S. Kumar, T. Hideshima, K. Ishitsuka, D. Chauhan, C. Mitsiades, K. Podar, S. Le Gouill, P. Richardson, N. C. Munshi, et al.
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Blood,
December 15, 2004;
104(13):
4188 - 4193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Schmidmaier, P. Baumann, M. Simsek, F. Dayyani, B. Emmerich, and G. Meinhardt
The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase
Blood,
September 15, 2004;
104(6):
1825 - 1832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
